Forcelead Technology Corp. (6996)

Overview

Antengene Corporation Limited is a pioneering biopharmaceutical entity focusing on the creation of innovative oncology treatments for patients across Greater China and the globe. Founded in 2016 and headquartered in Shanghai, China, the company stands at the forefront of cancer therapy research and development. It has made significant strides in advancing a range of therapeutic solutions aimed at addressing various hematological malignancies and solid tumors. Through its development of commercialized assets and a robust pipeline of late-stage product candidates and clinical stage assets, as well as pre-clinical stage assets, Antengene Corporation Limited is shaping the future of oncology therapy.

Products and Services

• ATG-010 (selinexor): An oral SINE compound used for treating multiple hematological malignancies and solid tumors. It is particularly effective in cases of relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, and Taiwan.
• ATG-008 (onatasertib): This orally available mTOR kinase inhibitor targets the treatment of solid tumors that harbor NFE2L2, STK11, RICTOR, and other specific genetic alterations, showing promise in its therapeutic applications.
• ATG-016: Identified as a second-generation XPO1 inhibitor, ATG-016 is currently under a Phase I/II clinical study for patients with high-risk myelodysplastic syndromes, showcasing its potential in disrupting cancer cell proliferation.
• ATG-017: An ERK1/2 inhibitor under development for the treatment of advanced solid tumors and hematologic malignancies, indicating a multi-faceted approach to oncology treatments.
• ATG-101: A PD-L1/4-1BB bispecific antibody in Phase I study intended for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma, demonstrating Antengene's commitment to innovative cancer therapy solutions.
• ATG-037: As a CD73 inhibitor, ATG-037 targets patients with advanced or metastatic solid tumors, providing a new avenue for immune-oncology strategies.
• ATG-018 & ATG-022: Among others, ATG-018, an ATR inhibitor, and ATG-022, a Claudin 18.2 antibody-drug conjugate, represent Antengene's diligent efforts in expanding their oncology portfolio with targeted treatments.
• ATG-031 & Other Pre-clinical Assets: ATG-031, an anti-CD24 monoclonal antibody, along with pre-clinical stage assets like ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor, underline the company's dedication to advancing research in immunotherapy and targeted cancer treatments.